BIO-CAT provides the very latest enzyme technology and custom formulations. Founded in 1988, our extensive range of products, from single-to-multi-enzyme blends, service various industrial, food, agriculture and other commercial markets. BIO-CAT is an FSSC 22000 certified facility in Virginia featuring state-of-the-art laboratories for scientific research, product development and on-site quality testing to better serve customers.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

FOOD MICROBIOLOGY TESTING MARKET 2020 IS BOOMING WORLDWIDE

Germany English News | April 08, 2020

news image

Food Microbiology Testing Market report provides an in-depth analysis of the overall market over a period from 2020-2026. The Food Microbiology Testing Market report also provides the market impact and new opportunities created due to the COVID19 catastrophe. The Food Microbiology Testing Market has been segmented based on different types and application. In order to provide a holistic view of the market current and future market, demand has been included in the report. The Food Microbiology Tes...

Read More

ANOTHER TAKEDA/SHIRE R&D EXEC JUMPS SHIP AS PHARVARIS NABS PENG LU AS ITS NEW CMO

FierceBiotech | February 07, 2020

news image

After getting off a $66 million series B round in September last year, hereditary angioedema (HAE) specialist Pharvaris has taken on a seasoned HAE developer to help lead its pipeline. The startup has nabbed former Takeda/Shire exec Peng Lu, M.D., Ph.D., as its chief medical officer; Lu comes from Shire after it has been subsumed into Japanese Big Pharma Takeda and follows a whole host of other execs who have hit the exit amid the merger. At Shire, she led the team that finished up the phase 3 p...

Read More

MEDTECH

PATRITUMAB DERUXTECAN GRANTED U.S. FDA BREAKTHROUGH THERAPY DESIGNATION IN PATIENTS WITH METASTATIC EGFR-MUTATED NON-SMALL CELL LUNG CANCER

Daiichi Sankyo | December 24, 2021

news image

Daiichi Sankyo Company, Limited announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to patritumab deruxtecan, a potential first-in-class HER3 directed antibody drug conjugate, for the treatment of patients with metastatic or locally advanced EGFR-mutated non-small cell lung cancer with disease progression on or after treatment with a third-generation tyrosine kinase inhibitor and platinum-based therapies. Lung cancer is the second most...

Read More

MEDTECH

TO SEARCH FOR NEW TREATMENTS DISEASES, UW OSHKOSH PARTNERED WITH FAUNA BIO

Fauna Bio | April 01, 2022

news image

A biotechnology business pioneering comparative, computational, and translational genomics, Fauna Bio, announced collaboration with the University of Wisconsin OshKosh to speed the translation of human treatments identified via research into extreme mammal adaption. Fauna Bio's sponsorship of UW Oshkosh with $500,000 expands the University's capability for biomedical partnerships and helps promote the University as a destination for academics exploring innovative animal models and ...

Read More
news image

FOOD MICROBIOLOGY TESTING MARKET 2020 IS BOOMING WORLDWIDE

Germany English News | April 08, 2020

Food Microbiology Testing Market report provides an in-depth analysis of the overall market over a period from 2020-2026. The Food Microbiology Testing Market report also provides the market impact and new opportunities created due to the COVID19 catastrophe. The Food Microbiology Testing Market has been segmented based on different types and application. In order to provide a holistic view of the market current and future market, demand has been included in the report. The Food Microbiology Tes...

Read More
news image

ANOTHER TAKEDA/SHIRE R&D EXEC JUMPS SHIP AS PHARVARIS NABS PENG LU AS ITS NEW CMO

FierceBiotech | February 07, 2020

After getting off a $66 million series B round in September last year, hereditary angioedema (HAE) specialist Pharvaris has taken on a seasoned HAE developer to help lead its pipeline. The startup has nabbed former Takeda/Shire exec Peng Lu, M.D., Ph.D., as its chief medical officer; Lu comes from Shire after it has been subsumed into Japanese Big Pharma Takeda and follows a whole host of other execs who have hit the exit amid the merger. At Shire, she led the team that finished up the phase 3 p...

Read More
news image

MEDTECH

PATRITUMAB DERUXTECAN GRANTED U.S. FDA BREAKTHROUGH THERAPY DESIGNATION IN PATIENTS WITH METASTATIC EGFR-MUTATED NON-SMALL CELL LUNG CANCER

Daiichi Sankyo | December 24, 2021

Daiichi Sankyo Company, Limited announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to patritumab deruxtecan, a potential first-in-class HER3 directed antibody drug conjugate, for the treatment of patients with metastatic or locally advanced EGFR-mutated non-small cell lung cancer with disease progression on or after treatment with a third-generation tyrosine kinase inhibitor and platinum-based therapies. Lung cancer is the second most...

Read More
news image

MEDTECH

TO SEARCH FOR NEW TREATMENTS DISEASES, UW OSHKOSH PARTNERED WITH FAUNA BIO

Fauna Bio | April 01, 2022

A biotechnology business pioneering comparative, computational, and translational genomics, Fauna Bio, announced collaboration with the University of Wisconsin OshKosh to speed the translation of human treatments identified via research into extreme mammal adaption. Fauna Bio's sponsorship of UW Oshkosh with $500,000 expands the University's capability for biomedical partnerships and helps promote the University as a destination for academics exploring innovative animal models and ...

Read More